Ipratropium Steri-Neb

How to order Ipratropium Steri-Neb

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Ipratropium Steri-Neb on Prescriptsy

Ipratropium Steri-Neb is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Ipratropium Steri-Neb is a prescription-only nebuliser solution containing ipratropium bromide, an anticholinergic (antimuscarinic) bronchodilator.

It is used to treat bronchospasm in patients with chronic obstructive pulmonary disease (COPD) and as an adjunct in acute severe or life-threatening asthma.

Each single-use Steri-Neb vial contains a pre-measured dose of ipratropium bromide in isotonic saline, available in strengths of 250 micrograms/1 mL and 500 micrograms/2 mL.

The solution is nebulised using a jet nebuliser driven by compressed air, producing a fine mist that is inhaled directly into the lungs.

Chronic obstructive pulmonary disease is one of the most common respiratory conditions in the United Kingdom, affecting an estimated 1.2 million people with a diagnosis, with many more thought to be undiagnosed.

COPD is characterised by progressive airflow limitation that is not fully reversible, caused predominantly by smoking and long-term exposure to inhaled irritants.

It encompasses chronic bronchitis (persistent productive cough) and emphysema (destruction of the alveolar walls).

Asthma, by contrast, is a chronic inflammatory airway disease characterised by variable airflow obstruction that is usually reversible, affecting approximately 5.4 million people in the UK.

In acute severe or life-threatening asthma, nebulised bronchodilators are a cornerstone of emergency treatment.

This page provides a detailed clinical overview of Ipratropium Steri-Neb, including how it works, clinical indications, dosage guidance, potential side effects, important safety warnings, and how it is prescribed in the United Kingdom.

Important safety information about Ipratropium Steri-Neb

Before reading further, note these essential safety points about ipratropium nebuliser solution.

• Ipratropium Steri-Neb is a prescription-only medicine (POM) for use with a jet nebuliser.
• Always use a mouthpiece rather than a face mask when possible to prevent the mist from reaching your eyes.
• Contact with the eyes can cause acute angle-closure glaucoma, a medical emergency. Seek immediate help if you develop sudden eye pain, redness, or blurred vision during or after nebulisation.
• Ipratropium is not a rescue bronchodilator. In acute asthma, always use it alongside salbutamol, not instead of it.
• Tell your doctor if you have glaucoma, an enlarged prostate, or difficulty passing urine.

Understanding COPD and acute asthma

COPD develops over many years, usually as a result of cigarette smoking, although occupational dust exposure, air pollution, and alpha-1 antitrypsin deficiency are also recognised causes.

Symptoms include progressive breathlessness, a persistent cough (often productive of sputum), frequent chest infections, and wheezing.

The diagnosis is confirmed by spirometry, which shows a post-bronchodilator FEV1/FVC ratio below 0.7.

COPD is classified by severity: mild (FEV1 80% or above predicted), moderate (50 to 79%), severe (30 to 49%), and very severe (below 30%).

NICE guideline NG115 provides the national framework for COPD diagnosis and management.

Acute asthma exacerbations range from moderate (increasing symptoms, peak expiratory flow 50 to 75% of best or predicted) to severe (peak flow 33 to 50%, unable to complete sentences, respiratory rate raised, heart rate raised) and life-threatening (peak flow below 33%, oxygen saturations below 92%, silent chest, cyanosis, altered consciousness).

BTS/SIGN guideline 158 and NICE guideline NG80 outline the acute management of asthma, in which high-dose nebulised salbutamol and ipratropium bromide, systemic corticosteroids, and supplemental oxygen are the mainstays of treatment.

How ipratropium works: mechanism of action

The airways are innervated by the parasympathetic (vagus) nervous system, which maintains a baseline level of bronchomotor tone.

Acetylcholine released from parasympathetic nerve endings acts on muscarinic receptors (predominantly M3 subtype) on airway smooth muscle, causing contraction and narrowing of the airways.

Acetylcholine also stimulates mucus secretion from submucosal glands via M3 receptors.

Ipratropium bromide is a competitive antagonist of muscarinic receptors.

By blocking acetylcholine at M3 receptors on bronchial smooth muscle, it prevents parasympathetic-driven bronchoconstriction and allows the airways to relax and widen.

It also reduces the volume of mucus secretion, although it does not affect the viscosity (thickness) of mucus. The net effect is bronchodilatation and reduced airway resistance.

Ipratropium is a quaternary ammonium compound, which means it carries a permanent positive charge and does not easily cross biological membranes.

This limits its systemic absorption from the lungs and gastrointestinal tract, confining its action primarily to the airways and reducing the risk of systemic anticholinergic side effects such as dry mouth, urinary retention, and tachycardia, though these can still occur.

The onset of bronchodilatation with ipratropium occurs within 15 minutes, reaching a peak at 1 to 2 hours, and the effect lasts 4 to 6 hours.

This is slower and longer-lasting than short-acting beta-2 agonists such as salbutamol (onset within 5 minutes, peak 15 to 30 minutes, duration 4 to 6 hours).

The two classes of bronchodilator work through complementary mechanisms, and their combination produces additive bronchodilatation, which is why they are frequently used together.

Clinical evidence and UK prescribing guidance

The role of ipratropium in COPD management is well established.

NICE NG115 recommends a short-acting bronchodilator (salbutamol or ipratropium) as initial therapy for breathlessness and exercise limitation in COPD.

For patients with persistent symptoms, long-acting bronchodilators (long-acting muscarinic antagonists such as tiotropium, or long-acting beta-2 agonists such as salmeterol) are added.

Nebulised ipratropium may be used in patients who are unable to use handheld inhalers effectively, in patients with severe COPD who require higher doses, and during acute exacerbations of COPD.

In acute asthma, the addition of nebulised ipratropium to salbutamol has been shown in systematic reviews and meta-analyses to improve lung function and reduce hospital admission rates compared with salbutamol alone, particularly in severe and life-threatening episodes.

BTS/SIGN guideline 158 recommends adding ipratropium bromide 500 micrograms to the initial salbutamol nebulisation in all patients with acute severe or life-threatening asthma.

In moderate exacerbations, the decision to add ipratropium is based on clinical judgement.

For maintenance COPD management, the evidence base favours long-acting anticholinergics (tiotropium, glycopyrronium, umeclidinium) over short-acting ipratropium because of their once-daily dosing, more sustained bronchodilatation, and demonstrated reduction in exacerbation frequency.

However, nebulised ipratropium retains an important role in patients who require nebuliser-delivered therapy due to severe airflow limitation, poor inhaler technique, or cognitive impairment.

Ipratropium compared with other bronchodilators

Short-acting beta-2 agonists (salbutamol and terbutaline) provide faster relief of acute bronchospasm than ipratropium and are the first-line reliever treatment in both asthma and COPD.

Ipratropium provides complementary bronchodilatation through a different mechanism and is most useful when added to a beta-2 agonist rather than used alone.

Pre-mixed nebuliser solutions containing ipratropium 500 micrograms and salbutamol 2.5 mg are available for convenience.

Long-acting muscarinic antagonists (LAMAs) such as tiotropium have largely replaced ipratropium for maintenance COPD therapy because of their once-daily dosing and superior evidence for reducing exacerbations.

However, nebulised ipratropium is still used acutely and in patients who require nebulised delivery for maintenance treatment.

Long-acting beta-2 agonists (LABAs) such as salmeterol and formoterol are used for maintenance bronchodilatation in both asthma (always with an inhaled corticosteroid) and COPD. They do not replace the acute role of nebulised ipratropium.

Dosage and administration

Ipratropium Steri-Neb is for inhalation via a jet nebuliser only. Do not inject or swallow the solution.

Use each Steri-Neb unit dose vial once and discard any remaining solution.

The solution should be clear and colourless; do not use if it appears discoloured or contains particles.

For adults with stable COPD, the usual dose is 250 to 500 micrograms nebulised 3 to 4 times daily.

For acute severe or life-threatening asthma in adults, 500 micrograms nebulised alongside salbutamol 5 mg is standard.

In hospital settings, nebulisation is driven by oxygen in acute asthma (unless the patient has type 2 respiratory failure with CO2 retention, in which case compressed air is used).

At home, compressed air is the standard driving gas.

Clean your nebuliser according to the manufacturer's instructions after each use and have it serviced regularly. Improper cleaning can lead to bacterial contamination of the device.

Side effects of ipratropium nebuliser solution

Common side effects

Dry mouth is the most frequently reported anticholinergic effect and is usually mild. Headache, cough, and throat irritation may occur due to the nebulised mist.

Nausea is reported occasionally. These effects are generally well tolerated and do not usually require treatment discontinuation.

Uncommon and rare side effects

Urinary retention is an uncommon but important anticholinergic effect, particularly in older men with prostatic enlargement. Palpitations, dizziness, and tremor are reported uncommonly.

Paradoxical bronchospasm is rare but serious; if wheezing worsens during nebulisation, stop immediately and use your salbutamol reliever. Allergic skin reactions (rash, urticaria) and anaphylaxis are very rare.

Eye complications

If nebulised ipratropium mist reaches the eyes, it can cause pupil dilatation (mydriasis), blurred vision, and, in patients with narrow angles, acute angle-closure glaucoma.

Symptoms include sudden severe eye pain, redness, haloes around lights, and visual loss. This is a medical emergency requiring urgent ophthalmological assessment.

Use a mouthpiece rather than a face mask to prevent ocular exposure.

When to seek urgent medical advice

Contact your GP or call NHS 111 if you experience persistent dry mouth, urinary difficulties, or skin rash.

Call 999 or attend A&E if you develop sudden eye pain with blurred vision (possible acute glaucoma), worsening breathlessness during nebulisation (paradoxical bronchospasm), difficulty breathing or swallowing with facial or throat swelling (anaphylaxis), or if your breathing deteriorates despite nebuliser treatment.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Glaucoma risk

Patients with narrow-angle glaucoma or a history of glaucoma must use ipratropium with extreme caution. Use a mouthpiece, not a face mask.

If both ipratropium and salbutamol are nebulised together, the risk of acute glaucoma may be additive. Inform your ophthalmologist that you use nebulised ipratropium.

Prostatic hypertrophy

Anticholinergic medicines can worsen urinary retention in men with benign prostatic hyperplasia. Monitor for symptoms of incomplete bladder emptying and seek medical advice if they occur.

Not a rescue treatment

Ipratropium should not be used as the sole bronchodilator for acute breathlessness. Its slower onset of action means it cannot replace salbutamol as a reliever. In acute asthma, it is an adjunct to, not a substitute for, beta-2 agonist therapy.

Drug interactions

Ipratropium has a favourable drug interaction profile. Combining it with other anticholinergic medicines (tiotropium, glycopyrronium, oxybutynin, amitriptyline) may increase the risk of systemic anticholinergic effects.

There are no significant interactions with inhaled corticosteroids, beta-2 agonists, leukotriene receptor antagonists, or oral corticosteroids.

Pregnancy and breastfeeding

The safety of ipratropium in pregnancy has not been established by controlled studies, but it has been in clinical use for decades without reports of teratogenicity.

Use during pregnancy should weigh benefits against risks. Breastfeeding mothers should consult their doctor, as it is not known whether ipratropium passes into breast milk.

How to get Ipratropium Steri-Neb in the UK

Ipratropium Steri-Neb is a prescription-only medicine available through the NHS. It is typically prescribed by a GP or respiratory specialist for patients who need nebulised therapy.

Home nebuliser therapy for COPD requires a clinical assessment to confirm that the patient cannot use handheld inhalers adequately and that nebulised treatment provides measurable benefit.

The NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Living with COPD and using nebulisers at home

If you have been prescribed a home nebuliser, your respiratory team should provide full training on how to set up the device, prepare the solution, nebulise the medication, and clean and maintain the equipment.

Nebuliser sessions typically last 10 to 15 minutes. Sit in an upright position and breathe normally through the mouthpiece or face mask.

Keep the device clean by washing the nebuliser chamber, mouthpiece, and tubing in warm soapy water after each use and allowing them to air-dry completely.

Replace consumable parts (chamber, tubing, filters) as recommended by the manufacturer.

Stopping smoking is the single most important intervention for slowing the progression of COPD.

The NHS offers free smoking cessation support through local Stop Smoking services, the NHS Smokefree helpline, and the NHS Quit Smoking app.

Pulmonary rehabilitation, an exercise and education programme, is strongly recommended for all patients with COPD who experience breathlessness on daily activities.

Annual influenza vaccination and pneumococcal vaccination are advised.

Attend regular reviews with your GP or respiratory nurse to monitor your lung function, review your inhaler technique, and adjust your treatment plan.

Sources

• Ipratropium Bromide Steri-Neb 500 micrograms/2 mL, Summary of Product Characteristics (EMC)
• Ipratropium bromide, British National Formulary (BNF)
• NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
• NICE NG80: Asthma: diagnosis, monitoring and chronic asthma management
• BTS/SIGN Guideline 158: British guideline on the management of asthma
• Chronic obstructive pulmonary disease (COPD), NHS
• MHRA Yellow Card Scheme